Ask AI
ProCE Banner Activity

The Activity and Safety of First-Generation TRK Inhibitors in NTRK Fusion–Positive Cancers

Slideset Download
Download these expert-selected slides on treating patients with NTRK-positive tumors with TRK inhibitors.

Released: June 11, 2021

Expiration: June 10, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Alexander E. Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York